Search research articles
Contact Us
Filters
Showing results (411-420 of 527) with videos related to
Page
of 53
Sort By:
The New England Journal of Medicine
|
December 14, 2016
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S Finn, Miguel Martin, Hope S Rugo, et al.
Journal of Hepatology
|
August 10, 2013
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
Richard S Finn, Ronnie T P Poon, Thomas Yau, et al.
Nature Materials
|
October 3, 2017
Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease
Nelly M Cruz, Xuewen Song, Stefan M Czerniecki, et al.
Journal of Hepatology
|
April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S Finn, Philippe Merle, Alessandro Granito, et al.
International Journal of Circumpolar Health
|
May 8, 2020
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
G G Alvarez, D Van Dyk, R Mallick, et al.
Journal of Hepatology
|
July 26, 2020
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro, Ignacio Melero, Samir Wadhawan, et al.
Liver Cancer
|
August 8, 2024
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Masatoshi Kudo, Richard S Finn, Masafumi Ikeda, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H S Rugo, R S Finn, V Diéras, et al.
Breast Cancer Research : BCR
|
June 29, 2016
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Richard S Finn, John P Crown, Johannes Ettl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Andrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Page
of 53
Search research articles
Search
Showing results (411-420 of 527) with videos related to
Sort By:
Page
of 53
The New England Journal of Medicine
|
December 14, 2016
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S Finn, Miguel Martin, Hope S Rugo, et al.
Journal of Hepatology
|
August 10, 2013
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
Richard S Finn, Ronnie T P Poon, Thomas Yau, et al.
Nature Materials
|
October 3, 2017
Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease
Nelly M Cruz, Xuewen Song, Stefan M Czerniecki, et al.
Journal of Hepatology
|
April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S Finn, Philippe Merle, Alessandro Granito, et al.
International Journal of Circumpolar Health
|
May 8, 2020
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
G G Alvarez, D Van Dyk, R Mallick, et al.
Journal of Hepatology
|
July 26, 2020
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro, Ignacio Melero, Samir Wadhawan, et al.
Liver Cancer
|
August 8, 2024
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Masatoshi Kudo, Richard S Finn, Masafumi Ikeda, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H S Rugo, R S Finn, V Diéras, et al.
Breast Cancer Research : BCR
|
June 29, 2016
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Richard S Finn, John P Crown, Johannes Ettl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Andrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Page
of 53